BioXcel to trial Apple Watch-drug combination to prevent Alzheimer’s agitation episodes

US biotech BioXcel Therapeutics hopes to use wearable digital devices such as the Apple Watch to predict whether patients with Alzheimer’s are becoming agitated, so that the company’s developmental drug BXCL501 can be administered to prevent the episode from escalating.